| |
| | CHI - Drug Discovery Japan |
 | | Drug Discovery Japan brings together leading researchers from around the world to discuss their experiences with many aspects of the drug discovery process from bioinformatics, proteomics, target identification and validation, to screening of combinatorial libraries, structure-based drug design, and ADME/Tox studies. |
 | | At the drug discovery stage, it is very important to provide information about critical aspects of PK/ADME of a candidate, including extent of absorption (transporter and insolubility), half-life, bioavailability, occurrence of active metabolite, major interspecies differences, inhibition and induction of CYPs (CYP1A1 or CYP3A4), and early in vitro studies in human tissues. |
 | | In keeping with other parts of the drug discovery process, lead optimization is thus heading for the age of informatics-driven predictive models to aid decision making and drug design. |
| www.healthtech.com /2002/mhj (5412 words) |
|